Ovarian function preservation in patients under chemotherapy treatment

Gynecological Endocrinology

Volumn 24, Issue 9, 2008, Pages 481-482

  Tempone, Antonio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GONADORELIN; MELPHALAN; METHOTREXATE; PACLITAXEL; PREDNISONE; PROCARBAZINE; SPHINGOSINE 1 PHOSPHATE; VINBLASTINE; VINCRISTINE;

AMENORRHEA; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EDITORIAL; HODGKIN DISEASE; HUMAN; LEUKEMIA; MELANOMA; MENOPAUSE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVARY CANCER; OVARY FUNCTION; OVARY INSUFFICIENCY; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; UTERINE CERVIX CARCINOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CRYOPRESERVATION; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MECHLORETHAMINE; NEOPLASMS; OOCYTES; OVARIAN FAILURE, PREMATURE; OVARY; RECOVERY OF FUNCTION; RISK FACTORS; YOUNG ADULT;

EID: 55049110194     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802296088     Document Type: Editorial

References (15)

1. Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol 2006;103:1109-1121.
2. Loibl S, Kohl J, Kaufmann J. [Reproduction after breast cancer: what advice do we have for our patients?] Zentralb Gynaekol 2005;127:120-124.
3. Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J, Fridman E. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Human Reprod 2007;22:1626-1633.
4. Goldhirch A, Gelber RD. Ann Oncol 1990;1:183-188.
5. Levine MN, Bramwell VH, et al. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-2658.
6. Bines J, Oleske DM, Cobleigh MA. J Clin Oncol 1996;14:1718-1729.
7. Lee SJ, Shover LR, et al. J Clin Oncol 2006;24:2919-2931.
8. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-2370.
9. Larsen, EC, Muller, J et al. JCEM 2003;88:5307-5314.
10. Lee SJ, Shover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
11. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP, Hakvoort-Cammel FG, van den Bos C, van den Berg H, Pieters R, de Muinck Keizer-Schrama SM. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007;92:3869-3874.
12. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006;11:422-434.
13. Lobo R. Potential options for preservation of fertility in women. N Engl J Med 2005;353:64-73.
14. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analog treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007;12:1055-1066.
15. Morita Y, Perez GI, Paris F, et al. Nat Med 2000;10:1109-1114.